Citation

Kim J, Davis M, Farchione T. J. Am. Med. Assoc. JAMA 2019; 321(11): 1104-1105.

Affiliation

Division of Psychiatry Products, US Food and Drug Administration, Silver Spring, Maryland.

Copyright

(Copyright © 2019, American Medical Association)

DOI

10.1001/jama.2018.21955

PMID

30874751

Abstract

To the Editor In a Viewpoint, Drs Sisti and Joffe1 expressed concern that interventions to reduce suicide have not been well studied in clinical trials and proposed inclusion of actively suicidal individuals in trials. The US Food and Drug Administration (FDA) provides regulatory advice on clinical trials for psychiatric drug development. We wish to comment on several issues in the article ...

Language: en